Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5557652 | Pharmacology & Therapeutics | 2017 | 17 Pages |
Abstract
The tumor suppressor p53 is one of the most important proteins for protection of genomic stability and cancer prevention. Cancers often inactivate it by either mutating its gene or disabling its function. Thus, activating p53 becomes an attractive approach for the development of molecule-based anti-cancer therapy. The past decade and half have witnessed tremendous progress in this area. This essay offers readers with a grand review on this progress with updated information about small molecule activators of p53 either still at bench work or in clinical trials.
Keywords
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacology
Authors
Daniel Nguyen, Wenjuan Liao, Shelya X. Zeng, Hua Lu,